[go: up one dir, main page]

MX2016011152A - Parche transdermico que contiene pramipexol para tratamiento de enfermedad neurodegenerativa. - Google Patents

Parche transdermico que contiene pramipexol para tratamiento de enfermedad neurodegenerativa.

Info

Publication number
MX2016011152A
MX2016011152A MX2016011152A MX2016011152A MX2016011152A MX 2016011152 A MX2016011152 A MX 2016011152A MX 2016011152 A MX2016011152 A MX 2016011152A MX 2016011152 A MX2016011152 A MX 2016011152A MX 2016011152 A MX2016011152 A MX 2016011152A
Authority
MX
Mexico
Prior art keywords
pramipexole
treatment
transdermal patch
tape
neurodegenerative disease
Prior art date
Application number
MX2016011152A
Other languages
English (en)
Inventor
Hamamoto Hidetoshi
Tatsumi Noboru
Takemoto Makiko
Original Assignee
Medrx Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medrx Co Ltd filed Critical Medrx Co Ltd
Publication of MX2016011152A publication Critical patent/MX2016011152A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Problema: Se proporciona una preparación no acuosa de cinta que demuestra absorción percutánea superior que contiene clorhidrato de pramipexol altamente cristalino que es pobremente soluble en solvente orgánico. Solución al problema: La presente invención permitió la producción de una preparación estable de cinta que demuestra la absorción percutánea superior, al usar la combinación de un líquido iónico basado en ácido graso, alcohol divalente y éster de ácido graso y al disolver en el mismo pramipexol. Como resultado, para el tratamiento de la enfermedad de Parkinson se puede proporcionar una preparación de cinta que contiene clorhidrato de pramipexol.
MX2016011152A 2014-02-27 2015-02-18 Parche transdermico que contiene pramipexol para tratamiento de enfermedad neurodegenerativa. MX2016011152A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014037584 2014-02-27
PCT/JP2015/054493 WO2015129527A1 (ja) 2014-02-27 2015-02-18 プラミペキソールを含有する神経変性疾患の治療用貼付剤

Publications (1)

Publication Number Publication Date
MX2016011152A true MX2016011152A (es) 2016-12-09

Family

ID=54008848

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016011152A MX2016011152A (es) 2014-02-27 2015-02-18 Parche transdermico que contiene pramipexol para tratamiento de enfermedad neurodegenerativa.

Country Status (5)

Country Link
US (1) US10045948B2 (es)
EP (1) EP3111935A4 (es)
JP (1) JPWO2015129527A1 (es)
MX (1) MX2016011152A (es)
WO (1) WO2015129527A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023144742A1 (en) 2022-01-26 2023-08-03 Universidade De Aveiro Ionic-liquid-based formulations for the prevention or treatment of neurological diseases

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3697399T3 (da) * 2017-10-18 2025-12-22 Intrabio Ltd Terapeutiske midler til anvendelse i behandlingen af uro i benene
PT3752141T (pt) * 2018-02-15 2024-07-11 Intrabio Ltd Acetil-leucina para utilizaçâo no tratamento do síndrome das pernas inquietas
CA3157143A1 (en) * 2019-10-11 2021-04-15 Toray Industries, Inc. Pharmaceutical composition containing temperature-responsive ionic liquid
EP4527376A1 (en) * 2022-05-16 2025-03-26 Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. Long-acting sustained-release preparation containing pramipexole and preparation method therefor
CN116650447B (zh) * 2023-04-24 2025-10-28 广州新济药业科技有限公司 凝胶贴膏剂及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3937271A1 (de) 1989-11-09 1991-05-16 Boehringer Ingelheim Kg Transdermale applikation von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
DE10137162A1 (de) * 2001-07-30 2003-02-20 Hexal Ag Matrixkontrolliertes transdermales therapeutisches System zur Anwendung von Pramiprexol und Ropinirol
DE10220230A1 (de) 2002-05-06 2003-11-27 Sanol Arznei Schwarz Gmbh Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms
DE10333393A1 (de) 2003-07-23 2005-02-24 Lts Lohmann Therapie-Systeme Ag Transdermales Therapeutisches System mit dem Wirkstoff Pramipexol
WO2006039532A2 (en) 2004-09-29 2006-04-13 Schwarz Pharma, Inc. Transdermal therapeutic system for parkinson’s disease
CN103239721B (zh) 2007-11-22 2016-03-16 美德阿利克斯株式会社 包括基于脂肪酸的离子型液体作为活性成分的外用制剂组合物
WO2011111384A1 (ja) 2010-03-11 2011-09-15 株式会社メドレックス パーキンソン病治療薬を含有する経皮用組成物
JP2012219044A (ja) 2011-04-06 2012-11-12 Nitto Denko Corp 貼付製剤
DK2865376T4 (da) 2012-06-20 2022-07-18 Medrx Co Ltd Klæbende præparatsammensætning opnået ved hjælp af blanding af lægemiddel, organisk opløsningsmiddel, lipofil salvebasis og pulver
CN103610666A (zh) 2013-12-11 2014-03-05 中国药科大学 一种盐酸普拉克索透皮贴剂及其制备方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023144742A1 (en) 2022-01-26 2023-08-03 Universidade De Aveiro Ionic-liquid-based formulations for the prevention or treatment of neurological diseases
US12514845B2 (en) 2022-01-26 2026-01-06 Universidade De Aveiro Ionic-liquid-based formulations for the prevention or treatment of neurological diseases

Also Published As

Publication number Publication date
EP3111935A4 (en) 2017-03-15
WO2015129527A1 (ja) 2015-09-03
EP3111935A1 (en) 2017-01-04
US20170014353A1 (en) 2017-01-19
US10045948B2 (en) 2018-08-14
JPWO2015129527A1 (ja) 2017-03-30

Similar Documents

Publication Publication Date Title
MX2016011152A (es) Parche transdermico que contiene pramipexol para tratamiento de enfermedad neurodegenerativa.
TN2014000356A1 (en) Heterocyclyl compounds as mek inhibitors
EP4371616A3 (en) Compositions of obeticholic acid and methods of use
MX363457B (es) Compuestos de sulfonamida heterociclica sustituida utiles como moduladores del canal del receptor de potencial transitorio a1 (trpa1).
MX375507B (es) Uso de derivados del ácido tetrámico como nematicidas.
BR112015027964A2 (pt) Compostos moduladores do regulador de condutância transmembrana da fibrose cística (cftr), composições farmacêuticas compreendendo os mesmos e uso destes para o tratamento da fibrose cística
EA201591051A1 (ru) Ингибиторы erk и варианты их применения
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
IN2014MN01962A (es)
HK1223911A1 (zh) 磷脂醯肌醇3-激酶抑制剂
EA201890641A2 (ru) СТИМУЛЯТОРЫ sGC
TR201904455T4 (tr) Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları.
MX367713B (es) Uso de derivados de pirazolopirimidina para el tratamiento de trastornos relacionados con la fosfoinositida 3-cinasa delta.
BR112015029495A2 (pt) compostos heterocíclicos como inibidores da via de sinalização hedgehog
MX2016011290A (es) Composiciones de ester de colina de acido lipoico y metodos de uso.
BR112015021524A2 (pt) derivados de sulfonil quinolina e usos dos mesmos
PH12019500467A1 (en) Benzo-fused heterocyclic derivatives useful agonists of gpr120
HK1216886A1 (zh) Ship1调节剂和与其相关的方法
MX357888B (es) Sales basicas de adicion de nitroxolina y usos de las mismas.
BR112016007526A2 (pt) formulação de tratamento contra hiv de atazanavir e cobicistat
IN2015DN01329A (es)
SA521420975B1 (ar) صيغ ذات تركيبة نانوية لتوصيل سيليبينين وعناصر نشطة أخرى لعلاج أمراض العين
SA521430930B1 (ar) مستحضر خارجي غير مائي يحتوي على ديكسميديتوميدين
EA201691825A1 (ru) Стабилизированный раствор на основе активных веществ, способ получения стабилизированного раствора активных веществ, фармацевтическая композиция на основе стабилизированного раствора активных веществ (два варианта)
NZ630125A (en) Herbal composition for the treatment of metabolic disorders